Low-Dose Naltrexone and Cancer: What the Research Actually Says

If you’ve spent any time in integrative oncology spaces, you’ve probably come across low-dose naltrexone, or LDN. It shows up in patient communities, in functional medicine discussions, and increasingly in the research literature. People talk about it with a kind of quiet enthusiasm, the kind reserved for things that seem almost too good to be true but keep showing up in the science anyway.

So what is it, does it actually work in cancer, and is it something worth exploring? Let me walk you through what we know.

A Drug with an Unexpected Second Life

Naltrexone has been around since the 1980s. It was originally developed to treat opioid addiction by blocking opioid receptors in the brain, essentially preventing the euphoric response that keeps people trapped in the cycle of dependence. At the standard therapeutic dose of 50mg daily, it does exactly that.

The story gets interesting when the dose comes way down.

Researchers and clinicians noticed something unexpected in patients who were tapering off naltrexone. At lower doses, somewhere between 1.5mg and 4.5mg, naltrexone appeared to have an entirely different set of effects. Instead of fully blocking opioid receptors, it created a brief, intermittent blockade that triggered a rebound increase in the body’s own endorphins and enkephalins, your natural feel-good, immune-regulating neuropeptides. [1]

Patients with autoimmune and chronic inflammatory conditions reported significant improvement. And then, over time, researchers started asking a deeper question: if LDN modulates immune function and inflammation at this level, what might it be doing in the context of cancer?

How LDN Works in the Cancer Context

There are three main mechanisms through which LDN is thought to influence cancer, and they’re distinct enough that it’s worth understanding each one.

The first is through your immune system. LDN’s brief, intermittent blockade of opioid receptors leads to a compensatory surge in your body’s own endorphins. This surge activates natural killer cells, the front-line immune cells that identify and destroy cancer cells, and stimulates T-cell activity. It also shifts macrophage polarization toward the M1 phenotype, which is the anti-tumor type of macrophage that helps the immune system attack cancer rather than shield it. A 2020 study in colorectal cancer demonstrated this M1 shift and showed that LDN promoted apoptosis in cancer cells through the Bax/Bcl-2/caspase-3/PARP signaling pathway. [2]

The second mechanism involves something called the opioid growth factor receptor axis, or OGF-OGFr axis, and this one is particularly fascinating. Your body produces a molecule called opioid growth factor that naturally suppresses cell proliferation by binding to its receptor on the cell surface. When LDN intermittently blocks that receptor, the body responds by upregulating both the growth factor and its receptor in a compensatory surge. The net effect is enhanced suppression of cancer cell proliferation and increased apoptosis. This pathway is active in a wide range of cancers including breast, lung, bladder, liver, lymphoma, and colon. [3, 4]

The third mechanism operates at the level of gene expression. Research has shown that LDN selectively upregulates pro-apoptotic genes and downregulates anti-apoptotic mediators in a pattern that’s distinct from what you’d see with standard naltrexone doses. This gene expression signature appears to be unique to the low-dose intermittent blockade, not simply a diluted version of what high-dose naltrexone does. [5]

What the Evidence Shows

It’s important to be honest here about where the evidence actually stands. Most of the data on LDN in cancer comes from cell culture studies, animal models, and a growing body of case reports and small clinical trials. The large randomized controlled trials that would allow definitive conclusions haven’t been completed yet. That doesn’t mean the evidence is weak. It means it’s early and it’s promising.

A 2024 systematic review published in Cancers examined the full body of preclinical and clinical evidence and concluded that LDN has high anti-cancer potential, particularly as an adjuvant alongside conventional chemotherapy and immunotherapy. [3] Pre-treatment with LDN has been shown to increase the sensitivity of cancer cells to platinum-based drugs like cisplatin and oxaliplatin, meaning those drugs become more effective in the presence of LDN. [6]

On the immune therapy side, a phase I clinical trial is currently underway testing LDN in combination with propranolol, ipilimumab, and nivolumab in patients with advanced melanoma. We’re watching that one closely. [3]

Something that doesn’t get mentioned often enough is LDN’s emerging role in cancer-related pain. A 2025 case series from MD Anderson Cancer Center reported that 80% of cancer patients who were prescribed LDN for refractory pain at their first follow-up experienced a positive response, with similar results at the second follow-up. The majority had breast cancer, and the most common dose was 3mg daily. Side effects were minor and didn’t require anyone to stop treatment. [7] For patients dealing with treatment-related neuropathy especially, this is a potentially meaningful finding.

Who LDN Isn’t Right For

This part matters, so please read it carefully.

LDN cannot be used alongside opioid pain medications. Because LDN works by blocking opioid receptors, it will directly counteract any opioid pain management you’re already on. This isn’t a minor interaction. It’s a fundamental incompatibility, and combining them without medical oversight can precipitate withdrawal. If you’re managing pain with opioids, LDN isn’t the right fit in that context, at least not at the same time.

LDN is an off-label use of a prescription medication. That means it requires a prescribing clinician who understands the mechanism, the dosing, the monitoring, and the context of your specific case. It’s not something to source independently or start without that clinical framework around it.

What to Expect If You Do Try It

For most people who are candidates, LDN is genuinely well-tolerated. The most commonly reported side effects, particularly in the first few weeks, are sleep disturbances and vivid dreams. This is thought to be related to the brief opioid receptor blockade happening overnight, when LDN is typically dosed. For most people it resolves within a few weeks as the body adjusts. Mild digestive symptoms like nausea or stomach discomfort are occasionally reported. These side effects are generally minor, and discontinuation rates in studies have been low. [7]

How I Think About LDN in Practice

LDN isn’t a standalone cancer treatment and it isn’t positioned as one in the serious literature. What it is, is a low-cost, relatively low-risk, mechanistically plausible adjuvant that may enhance immune function, suppress cancer cell proliferation through a distinct pathway, potentially sensitize cancer cells to conventional treatments, and support quality of life in ways that matter to patients every day.

When you’re navigating a cancer diagnosis and weighing every available tool, that combination is worth a serious conversation. The question isn’t whether LDN is a cure. It isn’t. The question is whether it might be one meaningful layer of a thoughtful, integrative protocol built around your specific diagnosis, your current treatment, and your biology.

That kind of thinking, precise, personalized, and grounded in both conventional and integrative evidence, is exactly what I do in practice. If you’re curious whether LDN belongs in your picture, I’d love to talk it through with you.

Work with Dr. Lena

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2

2. Ma M, Wang X, Liu N, Shan F, Feng Y. Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/Caspase-3/PARP pathway. Int Immunopharmacol. 2020;83:106388. doi:10.1016/j.intimp.2020.106388

3. Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Low-dose naltrexone as an adjuvant in combined anticancer therapy. Cancers. 2024;16(6):1240. doi:10.3390/cancers16061240

4. Aboalsoud A, El-Ghaiesh SH, Abd Elmonem FF, Salem ML, Abdel Rahman MN. The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: the role of OGFr, BCL2, and immune response. Int Immunopharmacol. 2020;78:106068. doi:10.1016/j.intimp.2019.106068

5. Liu WM, Scott KA, Dennis JL, et al. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy. Int J Oncol. 2016;49(2):793-802. doi:10.3892/ijo.2016.3567

6. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med. 2011;236(7):883-895. doi:10.1258/ebm.2011.011096

7. Mahajan A, Ye A, Chung M. Low dose naltrexone for refractory cancer pain: case series of initial safety and effectiveness. J Pain Symptom Manage. 2025;70(6):e492-e497. doi:10.1016/j.jpainsymman.2025.08.015

This article is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Please consult with a qualified integrative oncologist or naturopathic physician before making changes to your medications or treatment plan, particularly if you are currently in cancer treatment.